Phio Pharmaceuticals Corp.
PHIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.00 | 0.02 | 0.02 |
| FCF Yield | -50.18% | -680.62% | -241.66% | -92.91% |
| EV / EBITDA | -1.19 | 0.65 | 0.57 | 0.81 |
| Quality | ||||
| ROIC | -156.40% | -139.39% | -104.11% | -60.79% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.99 | 0.99 | 1.06 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | 33.86% | 12.21% | -2.86% | -35.01% |
| Safety | ||||
| Net Debt / EBITDA | 0.73 | 0.79 | 1.02 | 1.77 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -25.35 | -37.87 | -40.55 | -11.62 |